{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T13:09:31Z","timestamp":1761743371199},"reference-count":14,"publisher":"Hindawi Limited","license":[{"start":{"date-parts":[[2010,1,1]],"date-time":"2010-01-01T00:00:00Z","timestamp":1262304000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Journal of Endocrinology"],"published-print":{"date-parts":[[2010]]},"abstract":"<jats:p><jats:italic>Background<\/jats:italic>. Management of multiple-endocrine neoplasia type 1- (MEN1-) associated hyperparathyroidism is associated with high recurrence rates and high surgical morbidity due to multiple neck explorations. Cinacalcet, a calcimimetic agent licensed for the treatment of secondary hyperparathyroidism and parathyroid carcinoma, may provide a medical alternative for the management of these complex patients.<jats:italic>Methods<\/jats:italic>. A prospective audit was performed of eight patients; three males and five females, aged 20\u201338 at diagnosis. Two patients commenced cinacalcet as primary treatment and six had previous surgery. Six patients had complications of hyperparathyroidism: renal calculi, renal dysfunction, and reduced bone mineral density. All were commenced on cinacalcet 30\u2009mg bd for MEN1 associated hyperparathyroidism; doses were subsequently reduced to 30\u2009mg od in four patients.<jats:italic>Results<\/jats:italic>. Significant reductions were observed in serum calcium and PTH measurements. Serum calcium reduced by a median of 0.35\u2009mmol\/L ( Wilcoxon Signed Rank). Serum PTH levels decreased by a median of 5.05\u2009pmol\/L (). There was no change in urine calcium. Duration ranged from 10\u201335 months with maintenance of control. Cinacalcet was well tolerated by six patients; one experienced nausea and one experienced diarrhoea.<jats:italic>Conclusion<\/jats:italic>. Cinacalcet is an effective and well-tolerated medical treatment for the management of complex primary hyperparathyroidism.<\/jats:p>","DOI":"10.1155\/2010\/906163","type":"journal-article","created":{"date-parts":[[2010,5,26]],"date-time":"2010-05-26T10:33:36Z","timestamp":1274870016000},"page":"1-4","source":"Crossref","is-referenced-by-count":48,"title":["Clinical Use of Cinacalcet in MEN1 Hyperparathyroidism"],"prefix":"10.1155","volume":"2010","author":[{"given":"V. J.","family":"Moyes","sequence":"first","affiliation":[{"name":"Department of Endocrinology, St. Bartholomew's Hospital, London EC1A 7BE, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. P.","family":"Monson","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, St. Bartholomew's Hospital, London EC1A 7BE, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. L.","family":"Chew","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, St. Bartholomew's Hospital, London EC1A 7BE, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. A.","family":"Akker","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, St. Bartholomew's Hospital, London EC1A 7BE, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"98","reference":[{"key":"1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.86.12.5658"},{"key":"2","doi-asserted-by":"publisher","DOI":"10.1001\/archsurg.134.10.1119"},{"key":"3","volume-title":"Multiple endocrine neoplasia type 1","year":"2001"},{"key":"4","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfh966"},{"key":"5","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2007-0585"},{"key":"6","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2004-0842"},{"key":"7","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2002-021597"},{"key":"8","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2002-021370"},{"issue":"1","key":"9","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1359\/jbmr.2001.16.1.113","volume":"16","year":"2001","journal-title":"Journal of Bone and Mineral Research"},{"key":"10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2008.03301.x"},{"issue":"2","key":"11","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1023\/A:1009980404404","volume":"1","year":"1999","journal-title":"Pituitary"},{"issue":"2","key":"12","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1159\/000199408","volume":"36","year":"1987","journal-title":"Digestion"},{"key":"13","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2001.00924.x"},{"key":"14","doi-asserted-by":"publisher","DOI":"10.1038\/ncpendmet0816"}],"container-title":["International Journal of Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/downloads.hindawi.com\/journals\/ije\/2010\/906163.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/downloads.hindawi.com\/journals\/ije\/2010\/906163.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/downloads.hindawi.com\/journals\/ije\/2010\/906163.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T10:01:27Z","timestamp":1559124087000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.hindawi.com\/journals\/ije\/2010\/906163\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010]]},"references-count":14,"alternative-id":["906163","906163"],"URL":"https:\/\/doi.org\/10.1155\/2010\/906163","relation":{},"ISSN":["1687-8337","1687-8345"],"issn-type":[{"value":"1687-8337","type":"print"},{"value":"1687-8345","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010]]}}}